Home » News » Leeds University at the MRC’s Festival of Medical Research
26 Oct 2018

Researchers from Queen’s University Belfast and the University of Leeds, as part of a pan-European partnership called the European Cancer Concord (ECC) ®, have won the prestigious 2018 European Health Award.

This award honours initiatives that help tackle some of Europe’s most pressing health challenges.

 

The award-winning project, entitled ‘The European Cancer Patient’s Bill of Rights: A Catalyst for Change and an empowerment tool for cancer patients across Europe’ involves an equal partnership between cancer patients, healthcare professionals and cancer researchers.

Professor Mark Lawler, Vice President of the European Cancer Concord (ECC), today received the award on behalf of ECCO during the opening ceremony of the European Health Forum Gastein, the premier European Health Policy Conference and an official event of the Austrian European Council Presidency. 

25 Jul 2018

Susan Richman from the Leeds Institute of Cancer and Pathology obtained £1120 from the Medical Research Council (MRC)  to fund a stand  at the MRC’s Festival of Medical Research.  The stand titled, ‘So, just what is personalised Medicine?’ was split into three sections, with the first aiming to bust the stigma around bowel cancer screening, incorporating a game and a competition.

SHOW ALL
News
Leeds University at the MRC’s Festival of Medical Research
25 Jul 2018



Susan Richman from the Leeds Institute of Cancer and Pathology obtained £1120 from the Medical Research Council (MRC)  to fund a stand  at the MRC’s Festival of Medical Research.  The stand titled, ‘So, just what is personalised Medicine?’ was split into three sections, with the first aiming to bust the stigma around bowel cancer screening, incorporating a game and a competition.

The second highlighted the work of the MRC-funded S-CORT Stratification in Colorectal Cancer, which accesses and retrieves colorectal tumour samples from around the UK (over 3000 in total) for molecular profiling. This aims to provide a wealth of information and help to guide researchers to identify which patients will respond to particular chemotherapy regimens, or radiotherapy regimens or indeed respond to targeted therapies.

The final stand highlighted the FOCUS4 clinical trial which recruits patients who have advanced bowel cancer. The trial works on the premise that molecular tests can be applied to patient tumours which can lead to the allocation of each patient to the therapy, where they are likely to gain the most benefit – the perfect example of personalised medicine in action.

» Back to News
PROJECT
MEMBERS
2015-2020
  • Oxford University King's College London Queen's University Belfast
  • University of Leeds University of Aberdeen Sanger Institute
  • University College London University of Birmingham Partnering to Advance Human Health